Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease

Interstitial lung disease (ILD) is the leading cause of mortality in SSc. Novel biomarkers are crucial to improve outcomes in SSc-ILD. We aimed to compare the performance of potential serum biomarkers of SSc-ILD that reflect different pathogenic processes: KL-6 and SP-D (epithelial injury), CCL18 (t...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2024-04, Vol.63 (4), p.962-969
Main Authors: Györfi, Andrea-Hermina, Filla, Tim, Dickel, Nicholas, Möller, Florian, Li, Yi-Nan, Bergmann, Christina, Matei, Alexandru-Emil, Harrer, Thomas, Kunz, Meik, Schett, Georg, Distler, Jörg H W
Format: Article
Language:English
Subjects:
Biomarkers
Chitinase-3-Like Protein 1
Humans
Lung Diseases, Interstitial - complications
Lung Diseases, Interstitial - etiology
Matrix Metalloproteinase 7
Mucin-1
Pulmonary Surfactant-Associated Protein D
Scleroderma, Systemic - diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interstitial lung disease (ILD) is the leading cause of mortality in SSc. Novel biomarkers are crucial to improve outcomes in SSc-ILD. We aimed to compare the performance of potential serum biomarkers of SSc-ILD that reflect different pathogenic processes: KL-6 and SP-D (epithelial injury), CCL18 (type 2 immune response), YKL-40 (endothelial injury and matrix remodelling) and MMP-7 (ECM remodelling). Baseline and follow-up serum samples from 225 SSc patients were analysed by ELISA. Progressive ILD was defined according to the 2022-ATS/ERS/JRS/ALAT guidelines. Linear mixed models and random forest models were used for statistical analyses. Serum levels of KL-6 [MD 35.67 (95% CI 22.44-48.89, P 
ISSN:1462-0324
1462-0332
1462-0332
DOI:10.1093/rheumatology/kead332